Advertisement

Digestive Diseases and Sciences

, Volume 54, Issue 7, pp 1386–1402 | Cite as

Avoiding Pitfalls: What an Endoscopist Should Know in Liver Transplantation—Part II

  • Sharad SharmaEmail author
  • Ahmet Gurakar
  • Cemalettin Camci
  • Nicolas Jabbour
Review

Abstract

Over the last decade the number of patients undergoing transplantation has increased. At the same time, effective peri- and postoperative care and better surgical techniques have resulted in greater numbers of recipients achieving long-term survival. Identification and effective management in the form of adequate treatment is essential, since any delay in diagnosis or treatment may result in graft loss or serious threat to patient’s life. Various aspects of endoscopic findings that can be commonly encountered among liver transplant recipients are discussed herein. Topics include: persistent and/or recurrent esophageal varices, reflux, Candida or cytomegalovirus (CMV) esophagitis, esophageal neoplasms, posttransplant peptic ulcer, biliary complications, posttransplant lymphoproliferative disorder (PTLD), Kaposi’s sarcoma, CMV colitis and inflammatory bowel disease, colonic neoplasms, Clostridium difficile infection, and graft versus host disease (GVHD).

Keywords

Endoscopy Liver transplant Varices Candida Reflux Esophagitis Neoplasm Peptic ulcer CMV PTLD Kaposi sarcoma Colitis Inflammatory bowel disease Clostridium difficile GVHD 

Notes

Acknowledgments

The authors wish to acknowledge Dr. Camci for help with the clinical photographs in the manuscript.

References

  1. 1.
  2. 2.
    Navasa M, Feu F, Garcia-Pagan JC, et al. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology. 1993;17:355–360.PubMedCrossRefGoogle Scholar
  3. 3.
    Kita Y, Harihara Y, Sano K, et al. Reversible hepatofugal portal flow after liver transplantation using a small-for-size graft from a living donor. Transpl Int. 2001;14:217–222. doi: 10.1111/j.1432-2277.2001.tb00048.x.PubMedCrossRefGoogle Scholar
  4. 4.
    Troisi R, Cammu G, Militerno G, et al. Modulation of portal graft inflow: a necessity in adult living-donor liver transplantation? Ann Surg. 2003;237:429–436. doi: 10.1097/00000658-200303000-00019.PubMedCrossRefGoogle Scholar
  5. 5.
    Tabasco-Minguillan J, Jain A, Naik M, et al. Gastrointestinal bleeding after liver transplantation. Transplantation. 1997;63:60–67. doi: 10.1097/00007890-199701150-00012.PubMedCrossRefGoogle Scholar
  6. 6.
    Hirata M, Kita Y, Harihara Y, et al. Gastrointestinal bleeding after living-related liver transplantation. Dig Dis Sci. 2002;47:2386–2388. doi: 10.1023/A:1020570901035.PubMedCrossRefGoogle Scholar
  7. 7.
    Hirata M, Harihara Y, Kitamura T, et al. The influence of donor age to graft volume increase rate in living donor liver transplantation. Transplant Proc. 2001;33:1416–1417. doi: 10.1016/S0041-1345(00)02534-3.PubMedCrossRefGoogle Scholar
  8. 8.
    Gertsch P, Stipa F, Ho J, Yuen ST, Luk I, Lauder IJ. Changes in hepatic portal resistance and in liver morphology during regeneration: in vitro study in rats. Eur J Surg. 1997;163:297–304.PubMedGoogle Scholar
  9. 9.
    Settmacher U, Nussler NC, Glanemann M, et al. Venous complications after orthotopic liver transplantation. Clin Transplant. 2000;14:235–241. doi: 10.1034/j.1399-0012.2000.140309.x.PubMedCrossRefGoogle Scholar
  10. 10.
    Dumortier J, Czyglik O, Poncet G, et al. Eversion thrombectomy for portal vein thrombosis during liver transplantation. Am J Transplant. 2002;2:934–938. doi: 10.1034/j.1600-6143.2002.21009.x.PubMedCrossRefGoogle Scholar
  11. 11.
    Sanchez-Bueno F, Hernandez Q, Ramirez P, et al. Vascular complications in a series of 300 orthotopic liver transplants. Transplant Proc. 1999;31:2409–2410. doi: 10.1016/S0041-1345(99)00406-6.PubMedCrossRefGoogle Scholar
  12. 12.
    Lerut J, Tzakis AG, Bron K, et al. Complications of venous reconstruction in human orthotopic liver transplantation. Ann Surg. 1987;205:404–414. doi: 10.1097/00000658-198704000-00011.PubMedCrossRefGoogle Scholar
  13. 13.
    Doria C, Marino IR. Acute portal vein thrombosis secondary to donor/recipient portal vein diameter mismatch after orthotopic liver transplantation: a case report. Int Surg. 2003;88:184–187.PubMedGoogle Scholar
  14. 14.
    Wang JT, Zhao HY, Liu YL. Portal vein thrombosis. Hepatobiliary Pancreat Dis Int. 2005;4:515–518.PubMedGoogle Scholar
  15. 15.
    Ozkan U, Oguzkurt L, Tercan F, Tokmak N. Percutaneous transhepatic thrombolysis in the treatment of acute portal venous thrombosis. Diagn Interv Radiol. 2006;12:105–107.PubMedGoogle Scholar
  16. 16.
    Sobhonslidsuk A, Reddy KR. Portal vein thrombosis: a concise review. Am J Gastroenterol. 2002;97:535–541. doi: 10.1111/j.1572-0241.2002.05527.x.PubMedCrossRefGoogle Scholar
  17. 17.
    Cherukuri R, Haskal ZJ, Naji A, Shaked A. Percutaneous thrombolysis and stent placement for the treatment of portal vein thrombosis after liver transplantation: long-term follow-up. Transplantation. 1998;65:1124–1126. doi: 10.1097/00007890-199804270-00018.PubMedCrossRefGoogle Scholar
  18. 18.
    Hidajat N, Stobbe H, Griesshaber V, Schroder RJ, Felix R. Portal vein thrombosis: etiology, diagnostic strategy, therapy and management. Vasa. 2005;34:81–92. doi: 10.1024/0301-1526.34.2.81.PubMedCrossRefGoogle Scholar
  19. 19.
    Rossi C, Zambruni A, Ansaloni F, et al. Combined mechanical and pharmacologic thrombolysis for portal vein thrombosis in liver-graft recipients and in candidates for liver transplantation. Transplantation. 2004;78:938–940. doi: 10.1097/01.TP.0000137104.38602.9F.PubMedCrossRefGoogle Scholar
  20. 20.
    Adani GL, Baccarani U, Risaliti A, Sponza M, Gasparini D, Bresadola F, et al. Percutaneous transhepatic portography for the treatment of early portal vein thrombosis after surgery. Cardiovasc Intervent Radiol. 2007;30:1222–1226.Google Scholar
  21. 21.
    Karasu Z, Hulagu S, Gurakar A, et al. High incidence of noninfectious esophagitis in orthotopic liver transplant (olt) recipients. J Okla State Med Assoc. 2001;94:43–45.PubMedGoogle Scholar
  22. 22.
    Akatsu T, Yoshida M, Kawachi S, et al. Consequences of living-donor liver transplantation for upper gastrointestinal lesions: high incidence of reflux esophagitis. Dig Dis Sci. 2006;51:2018–2022. doi: 10.1007/s10620-006-9362-3.PubMedCrossRefGoogle Scholar
  23. 23.
    Kaur S, Kaur U, Agnihotri N, Tandon CD, Majumdar S. Modulation of acid secretion in common bile duct ligation-related gastropathy in wistar rats. J Gastroenterol Hepatol. 2001;16:755–762. doi: 10.1046/j.1440-1746.2001.02505.x.PubMedCrossRefGoogle Scholar
  24. 24.
    Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut. 2001;49:330–334. doi: 10.1136/gut.49.3.330.PubMedCrossRefGoogle Scholar
  25. 25.
    Shirota T, Kusano M, Kawamura O, Horikoshi T, Mori M, Sekiguchi T. Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings. J Gastroenterol. 1999;34:553–559. doi: 10.1007/s005350050372.PubMedCrossRefGoogle Scholar
  26. 26.
    Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am. 2003;17:113–134. doi: 10.1016/S0891-5520(02)00067-3
  27. 27.
    Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am. 1995;9:1045–1074.PubMedGoogle Scholar
  28. 28.
    Baehr PH, McDonald GB. Esophageal infections: risk factors, presentation, diagnosis, and treatment. Gastroenterology. 1994;106:509–532.PubMedGoogle Scholar
  29. 29.
    Kaufman DB, Leventhal JR, Koffron A, et al. Simultaneous pancreas-kidney transplantation in the mycophenolate mofetil/tacrolimus era: evolution from induction therapy with bladder drainage to noninduction therapy with enteric drainage. Surgery. 2000;128:726–737. doi: 10.1067/msy.2000.108424.PubMedCrossRefGoogle Scholar
  30. 30.
    Verduyn Lunel FM, Meis JF, Voss A. Nosocomial fungal infections: candidemia. Diagn Microbiol Infect Dis. 1999;34:213–220. doi: 10.1016/S0732-8893(99)00035-8.PubMedCrossRefGoogle Scholar
  31. 31.
    Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole vs. itraconazole-flucytosine association in the treatment of esophageal candidiasis in aids patients. A double-blind, multicenter placebo-controlled study. The candida esophagitis multicenter italian study (cemis) group. Chest. 1996;110:1507–1514. doi: 10.1378/chest.110.6.1507.PubMedCrossRefGoogle Scholar
  32. 32.
    Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of iowa organisms study. J Clin Microbiol. 2002;40:1298–1302. doi: 10.1128/JCM.40.4.1298-1302.2002.PubMedCrossRefGoogle Scholar
  33. 33.
    Wilcox CM, Alexander LN, Clark WS, Thompson SE 3rd. Fluconazole compared with endoscopy for human immunodeficiency virus-infected patients with esophageal symptoms. Gastroenterology. 1996;110:1803–1809. doi: 10.1053/gast.1996.v110.pm8964406.PubMedCrossRefGoogle Scholar
  34. 34.
    Husain S, Tollemar J, Dominguez EA, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation. 2003;75:2023–2029. doi: 10.1097/01.TP.0000065178.93741.72.PubMedCrossRefGoogle Scholar
  35. 35.
    Gaissert HA, Breuer CK, Weissburg A, Mermel L. Surgical management of necrotizing candida esophagitis. Ann Thorac Surg. 1999;67:231–233. doi: 10.1016/S0003-4975(98)01144-8.PubMedCrossRefGoogle Scholar
  36. 36.
    Gupta KL, Ghosh AK, Kochhar R, Jha V, Chakrabarti A, Sakhuja V. Esophageal candidiasis after renal transplantation: comparative study in patients on different immunosuppressive protocols. Am J Gastroenterol. 1994;89:1062–1065.PubMedGoogle Scholar
  37. 37.
    Singh N. Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis. 2000;31:545–553. doi: 10.1086/313943.PubMedCrossRefGoogle Scholar
  38. 38.
    Karchmer AW, Samore MH, Hadley S, Collins LA, Jenkins RL, Lewis WD. Fungal infections complicating orthotopic liver transplantation. Trans Am Clin Climatol Assoc. 1994;106:38–47. discussion 47–38.Google Scholar
  39. 39.
    Gabardi S, Kubiak DW, Chandraker AK, Tullius SG. Invasive fungal infections and antifungal therapies in solid organ transplant recipients. Transpl Int. 2007;20:993–1015.Google Scholar
  40. 40.
    Winston DJ, Emmanouilides C, Busuttil RW. Infections in liver transplant recipients. Clin Infect Dis. 1995;21:1077–1089. quiz 1090–1071.Google Scholar
  41. 41.
    Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol. 2005;16:1758–1774. doi: 10.1681/ASN.2004121113.PubMedCrossRefGoogle Scholar
  42. 42.
    Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. The dynamics of human cytomegalovirus replication in vivo. J Exp Med. 1999;190:177–182. doi: 10.1084/jem.190.2.177.PubMedCrossRefGoogle Scholar
  43. 43.
    Dominguez EA. Long-term infectious complications of liver transplantation. Semin Liver Dis. 1995;15:133–138.PubMedCrossRefGoogle Scholar
  44. 44.
    Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with cmv disease. J Infect Dis. 2002;186:829–833. doi: 10.1086/342601.PubMedCrossRefGoogle Scholar
  45. 45.
    Schnitzler MA, Lowell JA, Hmiel SP, et al. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: the importance of hla-dr matching. J Am Soc Nephrol. 2003;14:780–785. doi: 10.1097/01.ASN.0000051599.09435.1E.PubMedCrossRefGoogle Scholar
  46. 46.
    Scott JC, Partovi N, Ensom MH. Ganciclovir in solid organ transplant recipients: is there a role for clinical pharmacokinetic monitoring? Ther Drug Monit. 2004;26:68–77. doi: 10.1097/00007691-200402000-00014.PubMedCrossRefGoogle Scholar
  47. 47.
    Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The oral ganciclovir international transplantation study group. Lancet. 1997;350:1729–1733. doi: 10.1016/S0140-6736(97)05535-9.PubMedCrossRefGoogle Scholar
  48. 48.
    McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs. 2001;61:1153–1183. doi: 10.2165/00003495-200161080-00016.PubMedCrossRefGoogle Scholar
  49. 49.
    Snydman DR. Counterpoint: prevention of cytomegalovirus (cmv) infection and cmv disease in recipients of solid organ transplants: the case for prophylaxis. Clin Infect Dis. 2005;40:709–712. doi: 10.1086/427509.PubMedCrossRefGoogle Scholar
  50. 50.
    Sagedal S, Hartmann A, Rollag H. The impact of early cytomegalovirus infection and disease in renal transplant recipients. Clin Microbiol Infect. 2005;11:518–530. doi: 10.1111/j.1469-0691.2005.01190.x.PubMedCrossRefGoogle Scholar
  51. 51.
    Hodson EM, Barclay PG, Craig JC, Jones C, Kable K, Strippoli GF, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2005;CD003774.Google Scholar
  52. 52.
    Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of cmv infection following lung transplantation. Am J Transplant. 2004;4:1635–1642. doi: 10.1111/j.1600-6143.2004.00571.x.PubMedCrossRefGoogle Scholar
  53. 53.
    Keven K, Basu A, Tan HP, et al. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Transplant Proc. 2004;36:3107–3112. doi: 10.1016/j.transproceed.2004.11.092.PubMedCrossRefGoogle Scholar
  54. 54.
    Taber DJ, Ashcraft E, Baillie GM, et al. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis. 2004;6:101–109. doi: 10.1111/j.1399-3062.2004.00066.x.PubMedCrossRefGoogle Scholar
  55. 55.
    Haagsma EB, Hagens VE, Schaapveld M, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol. 2001;34:84–91. doi: 10.1016/S0168-8278(00)00077-5.PubMedCrossRefGoogle Scholar
  56. 56.
    Herrero JI, Lorenzo M, Quiroga J, et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl. 2005;11:89–97. doi: 10.1002/lt.20319.PubMedCrossRefGoogle Scholar
  57. 57.
    Yao FY, Gautam M, Palese C, et al. De novo malignancies following liver transplantation: a case-control study with long-term follow-up. Clin Transplant. 2006;20:617–623. doi: 10.1111/j.1399-0012.2006.00527.x.PubMedCrossRefGoogle Scholar
  58. 58.
    Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 2004;10:534–540. doi: 10.1002/lt.20128.PubMedCrossRefGoogle Scholar
  59. 59.
    Sanchez W, Talwalkar JA, Gores GJ. Will all liver transplantation patients eventually die from cancer? J Hepatol. 2006;44:13–18. doi: 10.1016/j.jhep.2005.10.007.PubMedCrossRefGoogle Scholar
  60. 60.
    Jain AB, Yee LD, Nalesnik MA, et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation. 1998;66:1193–1200. doi: 10.1097/00007890-199811150-00014.PubMedCrossRefGoogle Scholar
  61. 61.
    Duvoux C, Delacroix I, Richardet JP, et al. Increased incidence of oropharyngeal squamous cell carcinomas after liver transplantation for alcoholic cirrhosis. Transplantation. 1999;67:418–421. doi: 10.1097/00007890-199902150-00014.PubMedCrossRefGoogle Scholar
  62. 62.
    Penn I. Cancers complicating organ transplantation. N Engl J Med. 1990;323:1767–1769.PubMedGoogle Scholar
  63. 63.
    Penn I. The problem of cancer in organ transplant recipients: an overview. Transplant Sci. 1994;4:23–32.PubMedGoogle Scholar
  64. 64.
    Diaz de Liano A, Artieda C, Yarnoz C, Garde C, Flores L, Ortiz H. Esophageal squamous cell carcinoma after liver transplantation. Clin Transl Oncol. 2005;7:518–520. doi: 10.1007/BF02717007.PubMedCrossRefGoogle Scholar
  65. 65.
    Trotter JF, Brazer SR. Rapid progression to high-grade dysplasia in barrett’s esophagus after liver transplantation. Liver Transpl Surg. 1999;5:332–333. doi: 10.1002/lt.500050405.PubMedCrossRefGoogle Scholar
  66. 66.
    Ilan Y, Shouval D, Galun E, et al. Esophageal malignancy after liver transplantation in a patient with barrett’s esophagus. Scand J Gastroenterol. 1996;31:415–416. doi: 10.3109/00365529609006420.PubMedCrossRefGoogle Scholar
  67. 67.
    Hassanein T, Gurakar A, Wright HI, Van Thiel DH. Major gastrointestinal bleeding occurring after liver transplantation. J Okla State Med Assoc. 1995;88:114–118.PubMedGoogle Scholar
  68. 68.
    Wood RP, Shaw BWJ, Starzl TE. Extrahepatic complications of liver transplantation. Semin Liver Dis. 1985;5:377–384.PubMedCrossRefGoogle Scholar
  69. 69.
    Hosotani Y, Kawanami C, Hasegawa K, et al. A role of Helicobacter pylori infection in the development of duodenal ulcer after adult living-related liver transplantation. Transplantation. 2003;76:702–704. doi: 10.1097/01.TP.0000080573.91725.0E.PubMedCrossRefGoogle Scholar
  70. 70.
    Maaroos HI, Kekki M, Vorobjova T, Salupere V, Sipponen P. Risk of recurrence of gastric ulcer, chronic gastritis, and grade of Helicobacter pylori colonization. A long-term follow-up study of 25 patients. Scand J Gastroenterol. 1994;29:532–536. doi: 10.3109/00365529409092468.PubMedCrossRefGoogle Scholar
  71. 71.
    Guilbeau JM. Delayed wound healing with sirolimus after liver transplant. Ann Pharmacother. 2002;36:1391–1395. doi: 10.1345/aph.1A128.PubMedCrossRefGoogle Scholar
  72. 72.
    Smith AD, Bai D, Marroquin CE, et al. Gastrointestinal hemorrhage due to complicated gastroduodenal ulcer disease in liver transplant patients taking sirolimus. Clin Transplant. 2005;19:250–254. doi: 10.1111/j.1399-0012.2005.00332.x.PubMedCrossRefGoogle Scholar
  73. 73.
    Starzl TE, Putnam CW, Hansbrough JF, Porter KA, Reid HA. Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery. 1977;81:212–221.PubMedGoogle Scholar
  74. 74.
    Greif F, Bronsther OL, Van Thiel DH, et al. The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg. 1994;219:40–45. doi: 10.1097/00000658-199401000-00007.PubMedCrossRefGoogle Scholar
  75. 75.
    Sharma S, Gurakar A, Jabbour N. Biliary strictures following liver transplantation: past, present and preventive strategies. Liver Transpl. 2008;14(6):759–769. doi: 10.1002/lt.21509.PubMedCrossRefGoogle Scholar
  76. 76.
    Liu CL, Lo CM, Chan SC, Fan ST. Safety of duct-to-duct biliary reconstruction in right-lobe live-donor liver transplantation without biliary drainage. Transplantation. 2004;77:726–732. doi: 10.1097/01.TP.0000116604.89083.2F.PubMedCrossRefGoogle Scholar
  77. 77.
    Rerknimitr R, Sherman S, Fogel EL, et al. Biliary tract complications after orthotopic liver transplantation with choledochocholedochostomy anastomosis: endoscopic findings and results of therapy. Gastrointest Endosc. 2002;55:224–231. doi: 10.1067/mge.2002.120813.PubMedCrossRefGoogle Scholar
  78. 78.
    Egawa H, Inomata Y, Uemoto S, et al. Biliary anastomotic complications in 400 living related liver transplantations. World J Surg. 2001;25:1300–1307. doi: 10.1007/s00268-001-0114-4.PubMedCrossRefGoogle Scholar
  79. 79.
    Shah SA, Grant DR, McGilvray ID, et al. Biliary strictures in 130 consecutive right lobe living donor liver transplant recipients: results of a Western center. Am J Transplant. 2007;7:161–167. doi: 10.1111/j.1600-6143.2006.01601.x.PubMedCrossRefGoogle Scholar
  80. 80.
    Hwang S, Lee SG, Sung KB, et al. Long-term incidence, risk factors, and management of biliary complications after adult living donor liver transplantation. Liver Transpl. 2006;12:831–838. doi: 10.1002/lt.20693.PubMedCrossRefGoogle Scholar
  81. 81.
    Yazumi S, Yoshimoto T, Hisatsune H, et al. Endoscopic treatment of biliary complications after right-lobe living-donor liver transplantation with duct-to-duct biliary anastomosis. J Hepatobiliary Pancreat Surg. 2006;13:502–510. doi: 10.1007/s00534-005-1084-y.PubMedCrossRefGoogle Scholar
  82. 82.
    Tashiro H, Itamoto T, Sasaki T, et al. Biliary complications after duct-to-duct biliary reconstruction in living-donor liver transplantation: causes and treatment. World J Surg. 2007;31:2222–2229. doi: 10.1007/s00268-007-9217-x.PubMedCrossRefGoogle Scholar
  83. 83.
    Campbell WL, Sheng R, Zajko AB, Abu-Elmagd K, Demetris AJ. Intrahepatic biliary strictures after liver transplantation. Radiology. 1994;191:735–740.PubMedGoogle Scholar
  84. 84.
    Ostroff JW. Post-transplant biliary problems. Gastrointest Endosc Clin North Am. 2001;11:163–183.Google Scholar
  85. 85.
    Moench C, Uhrig A, Lohse AW, Otto G. CC chemokine receptor 5delta32 polymorphism-a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation. Liver Transpl. 2004;10:434–439. doi: 10.1002/lt.20095.PubMedCrossRefGoogle Scholar
  86. 86.
    Schlitt HJ, Meier PN, Nashan B, et al. Reconstructive surgery for ischemic-type lesions at the bile duct bifurcation after liver transplantation. Ann Surg. 1999;229:137–145. doi: 10.1097/00000658-199901000-00018.PubMedCrossRefGoogle Scholar
  87. 87.
    Graziadei IW, Schwaighofer H, Koch R, et al. Long-term outcome of endoscopic treatment of biliary strictures after liver transplantation. Liver Transpl. 2006;12:718–725. doi: 10.1002/lt.20644.PubMedCrossRefGoogle Scholar
  88. 88.
    Maheshwari A, Maley W, Li Z, Thuluvath PJ. Biliary complications and outcomes of liver transplantation from donors after cardiac death. Liver Transpl. 2007;13:1645–1653. doi: 10.1002/lt.21212.PubMedCrossRefGoogle Scholar
  89. 89.
    Fung JJ, Eghtesad B, Patel-Tom K. Using livers from donation after cardiac death donors: a proposal to protect the true Achilles hell. Liver Transpl. 2007;13:1633–1636. doi: 10.1002/lt.21388.PubMedCrossRefGoogle Scholar
  90. 90.
    Moench C, Moench K, Lohse AW, Thies J, Otto G. Prevention of ischemic-type biliary lesions by arterial back-table pressure perfusion. Liver Transpl. 2003;9:285–289. doi: 10.1053/jlts.2003.50015.PubMedCrossRefGoogle Scholar
  91. 91.
    Schwartz DA, Petersen BT, Poterucha JJ, Gostout CJ. Endoscopic therapy of anastomotic bile duct strictures occurring after liver transplantation. Gastrointest Endosc. 2000;51:169–174. doi: 10.1016/S0016-5107(00)70413-5.PubMedCrossRefGoogle Scholar
  92. 92.
    Morelli J, Mulcahy HE, Willner IR, Cunningham JT, Draganov P. Long-term outcomes for patients with post-liver transplant anastomotic biliary strictures treated by endoscopic stent placement. Gastrointest Endosc. 2003;58:374–379. doi: 10.1067/S0016-5107(03)00011-7.PubMedCrossRefGoogle Scholar
  93. 93.
    Wright H, Sharma S, Gurakar A, Sebastian A, Kohli V, Jabbour N. Management of biliary stricture guided by the Spyglass Direct Visualization System in a liver transplant recipient: an innovative approach. Gastrointest Endosc. 2008;67(7):1201–1203. doi: 10.1016/j.gie.2007.10.055.PubMedCrossRefGoogle Scholar
  94. 94.
    Chen YK, Pleskow DK. SpyGlass single-operator peroral cholangiopancreatoscopy system for the diagnosis and therapy of bile-duct disorders: a clinical feasibility study (with video). Gastrointest Endosc. 2007;65(6):832–841. doi: 10.1016/j.gie.2007.01.025.PubMedCrossRefGoogle Scholar
  95. 95.
    Canelo R, Hakim NS, Ringe B. Experience with hystidine tryptophan ketoglutarate versus University Wisconsin preservation solutions in transplantation. Int Surg. 2003;88:145–151.PubMedGoogle Scholar
  96. 96.
    Penn I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg. 1996;2:52–59. doi: 10.1002/lt.500020109.PubMedCrossRefGoogle Scholar
  97. 97.
    Adami J, Gabel H, Lindelof B, et al. Cancer risk following organ transplantation: a nationwide cohort study in sweden. Br J Cancer. 2003;89:1221–1227. doi: 10.1038/sj.bjc.6601219.PubMedCrossRefGoogle Scholar
  98. 98.
    Ravat FE, Spittle MF, Russell-Jones R. Primary cutaneous t-cell lymphoma occurring after organ transplantation. J Am Acad Dermatol. 2006;54:668–675. doi: 10.1016/j.jaad.2005.10.015.PubMedCrossRefGoogle Scholar
  99. 99.
    Rajakariar R, Bhattacharyya M, Norton A, et al. Post transplant t-cell lymphoma: a case series of four patients from a single unit and review of the literature. Am J Transplant. 2004;4:1534–1538. doi: 10.1111/j.1600-6143.2004.00521.x.PubMedCrossRefGoogle Scholar
  100. 100.
    Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg. 1988;25:367–472. doi: 10.1016/0011-3840(88)90011-1.PubMedCrossRefGoogle Scholar
  101. 101.
    Caillard S, Agodoa LY, Bohen EM, Abbott KC. Myeloma, hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation. 2006;81:888–895. doi: 10.1097/01.tp.0000203554.54242.56.PubMedCrossRefGoogle Scholar
  102. 102.
    Hanto DW. Classification of epstein-barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med. 1995;46:381–394. doi: 10.1146/annurev.med.46.1.381.PubMedCrossRefGoogle Scholar
  103. 103.
    Patton DF, Wilkowski CW, Hanson CA, et al. Epstein-barr virus-determined clonality in posttransplant lymphoproliferative disease. Transplantation. 1990;49:1080–1084. doi: 10.1097/00007890-199006000-00010.PubMedCrossRefGoogle Scholar
  104. 104.
    Randhawa PS, Jaffe R, Demetris AJ, et al. Expression of epstein-barr virus-encoded small rna (by the eber-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med. 1992;327:1710–1714.PubMedGoogle Scholar
  105. 105.
    Young L, Alfieri C, Hennessy K, et al. Expression of epstein-barr virus transformation-associated genes in tissues of patients with ebv lymphoproliferative disease. N Engl J Med. 1989;321:1080–1085.PubMedGoogle Scholar
  106. 106.
    Scheenstra R, Verschuuren EA, de Haan A, et al. The value of prospective monitoring of epstein-barr virus DNA in blood samples of pediatric liver transplant recipients. Transpl Infect Dis. 2004;6:15–22. doi: 10.1111/j.1399-3062.2004.00044.x.PubMedCrossRefGoogle Scholar
  107. 107.
    Kogan DL, Burroughs M, Emre S, et al. Prospective longitudinal analysis of quantitative epstein-barr virus polymerase chain reaction in pediatric liver transplant recipients. Transplantation. 1999;67:1068–1070. doi: 10.1097/00007890-199904150-00023.PubMedCrossRefGoogle Scholar
  108. 108.
    Orentas RJ, Schauer DWJ, Ellis FW, Walczak J, Casper JT, Margolis DA. Monitoring and modulation of epstein-barr virus loads in pediatric transplant patients. Pediatr Transplant. 2003;7:305–314. doi: 10.1034/j.1399-3046.2003.00090.x.PubMedCrossRefGoogle Scholar
  109. 109.
    Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating epstein-barr virus (ebv)-infected lymphocytes and decreased ebv nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood. 1994;84:972–984.PubMedGoogle Scholar
  110. 110.
    Rowe DT, Qu L, Reyes J, et al. Use of quantitative competitive pcr to measure epstein-barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol. 1997;35:1612–1615.PubMedGoogle Scholar
  111. 111.
    Yancoski J, Danielian S, Ibanez J, et al. Quantification of epstein-barr virus load in argentinean transplant recipients using real-time pcr. J Clin Virol. 2004;31:58–65. doi: 10.1016/j.jcv.2004.02.015.PubMedCrossRefGoogle Scholar
  112. 112.
    Poirel HA, Bernheim A, Schneider A, et al. Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: correlation with histopathological subcategories and ebv status. Transplantation. 2005;80:176–184. doi: 10.1097/01.TP.0000163288.98419.0D.PubMedCrossRefGoogle Scholar
  113. 113.
    Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg. 2002;236:429–436. discussion 436–427. doi: 10.1097/00000658-200210000-00005 Google Scholar
  114. 114.
    Leblond V, Choquet S. Lymphoproliferative disorders after liver transplantation. J Hepatol. 2004;40:728–735. doi: 10.1016/j.jhep.2004.03.006.PubMedCrossRefGoogle Scholar
  115. 115.
    Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH. Epstein-barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol. 2000;24:375–385. doi: 10.1097/00000478-200003000-00006.PubMedCrossRefGoogle Scholar
  116. 116.
    Koch DG, Christiansen L, Lazarchick J, Stuart R, Willner IR, Reuben A. Posttransplantation lymphoproliferative disorder––the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of epstein-barr virus. Liver Transpl. 2007;13:904–912. doi: 10.1002/lt.21152.PubMedCrossRefGoogle Scholar
  117. 117.
    Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation. 2005;80:1233–1243. doi: 10.1097/01.tp.0000179639.98338.39.PubMedCrossRefGoogle Scholar
  118. 118.
    Opelz G, Naujokat C, Daniel V, Terness P, Dohler B. Disassociation between risk of graft loss and risk of non-hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation. 2006;81:1227–1233. doi: 10.1097/01.tp.0000219817.18049.36.PubMedCrossRefGoogle Scholar
  119. 119.
    Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis. 1995;20:1346–1353.PubMedGoogle Scholar
  120. 120.
    Shahinian VB, Muirhead N, Jevnikar AM, et al. Epstein-barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients. Transplantation. 2003;75:851–856. doi: 10.1097/01.TP.0000055098.96022.F7.PubMedCrossRefGoogle Scholar
  121. 121.
    Zangwill SD, Hsu DT, Kichuk MR, et al. Incidence and outcome of primary epstein-barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. J Heart Lung Transplant. 1998;17:1161–1166.PubMedGoogle Scholar
  122. 122.
    Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine a-prednisone immunosuppression. Am J Pathol. 1988;133:173–192.PubMedGoogle Scholar
  123. 123.
    Kew CE 2nd, Lopez-Ben R, Smith JK, et al. Postransplant lymphoproliferative disorder localized near the allograft in renal transplantation. Transplantation. 2000;69:809–814. doi: 10.1097/00007890-200003150-00023.PubMedCrossRefGoogle Scholar
  124. 124.
    Younes BS, Ament ME, McDiarmid SV, Martin MG, Vargas JH. The involvement of the gastrointestinal tract in posttransplant lymphoproliferative disease in pediatric liver transplantation. J Pediatr Gastroenterol Nutr. 1999;28:380–385. doi: 10.1097/00005176-199904000-00007.PubMedCrossRefGoogle Scholar
  125. 125.
    Lai YC, Ni YH, Jou ST, et al. Post-transplantation lymphoproliferative disorders localizing to the gastrointestinal tract after liver transplantation: report of five pediatric cases. Pediatr Transplant. 2006;10:390–394. doi: 10.1111/j.1399-3046.2005.00457.x.PubMedCrossRefGoogle Scholar
  126. 126.
    Heo JS, Park JW, Lee KW, et al. Posttransplantation lymphoproliferative disorder in pediatric liver transplantation. Transplant Proc. 2004;36:2307–2308. doi: 10.1016/j.transproceed.2004.08.138.PubMedCrossRefGoogle Scholar
  127. 127.
    Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1:583–587. doi: 10.1016/S0140-6736(84)90994-2.PubMedCrossRefGoogle Scholar
  128. 128.
    Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71:1076–1088. doi: 10.1097/00007890-200104270-00012.PubMedCrossRefGoogle Scholar
  129. 129.
    Armitage JM, Kormos RL, Stuart RS, Fricker FJ, Griffith BP, Nalesnik M, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant. 1991;10:877–886. discussion 886–877.Google Scholar
  130. 130.
    Oertel S, Trappe RU, Zeidler K, et al. Epstein-barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Ann Hematol. 2006;85:478–484. doi: 10.1007/s00277-006-0109-1.PubMedCrossRefGoogle Scholar
  131. 131.
    Yang J, Tao Q, Flinn IW, et al. Characterization of epstein-barr virus-infected b cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood. 2000;96:4055–4063.PubMedGoogle Scholar
  132. 132.
    Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis. 2001;3:79–87. doi: 10.1034/j.1399-3062.2001.003002079.x.PubMedCrossRefGoogle Scholar
  133. 133.
    Green M, Cacciarelli TV, Mazariegos GV, et al. Serial measurement of epstein-barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation. 1998;66:1641–1644. doi: 10.1097/00007890-199812270-00012.PubMedCrossRefGoogle Scholar
  134. 134.
    Trofe J, Buell JF, Beebe TM, et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the israel penn international transplant tumor registry experience. Am J Transplant. 2005;5:775–780. doi: 10.1111/j.1600-6143.2005.00776.x.PubMedCrossRefGoogle Scholar
  135. 135.
    Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol. 2005;23:7574–7582. doi: 10.1200/JCO.2005.01.0934.PubMedCrossRefGoogle Scholar
  136. 136.
    Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of epstein-barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood. 2001;97:1165–1171. doi: 10.1182/blood.V97.5.1165.PubMedCrossRefGoogle Scholar
  137. 137.
    Matsukura T, Yokoi A, Egawa H, et al. Significance of serial real-time pcr monitoring of ebv genome load in living donor liver transplantation. Clin Transplant. 2002;16:107–112. doi: 10.1034/j.1399-0012.2002.1o112.x.PubMedCrossRefGoogle Scholar
  138. 138.
    Bodova I, Horakova J, Lukac J, Cupanikova D, Plank L. Autoimmune hemolytic anemia and chronic giant cell hepatitis. Bratisl Lek Listy (Tlacene Vyd). 2000;101:54–56. Google Scholar
  139. 139.
    Penn I. Kaposi’s sarcoma in transplant recipients. Transplantation. 1997;64:669–673. doi: 10.1097/00007890-199709150-00001.PubMedCrossRefGoogle Scholar
  140. 140.
    Miller G, Rigsby MO, Heston L, et al. Antibodies to butyrate-inducible antigens of kaposi’s sarcoma-associated herpesvirus in patients with hiv-1 infection. N Engl J Med. 1996;334:1292–1297. doi: 10.1056/NEJM199605163342003.PubMedCrossRefGoogle Scholar
  141. 141.
    Munoz P, Alvarez P, de Ory F, Pozo F, Rivera M, Bouza E. Incidence and clinical characteristics of kaposi sarcoma after solid organ transplantation in Spain: importance of seroconversion against hhv-8. Medicine (Baltimore). 2002;81:293–304. doi: 10.1097/00005792-200207000-00005.CrossRefGoogle Scholar
  142. 142.
    Qunibi W, Al-Furayh O, Almeshari K, et al. Serologic association of human herpesvirus eight with posttransplant kaposi’s sarcoma in Saudi Arabia. Transplantation. 1998;65:583–585. doi: 10.1097/00007890-199802270-00024.PubMedCrossRefGoogle Scholar
  143. 143.
    Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681–1691. doi: 10.1056/NEJMra022137.PubMedCrossRefGoogle Scholar
  144. 144.
    Aseni P, Vertemati M, Minola E, et al. Kaposi’s sarcoma in liver transplant recipients: morphological and clinical description. Liver Transpl. 2001;7:816–823. doi: 10.1053/jlts.2001.26925.PubMedCrossRefGoogle Scholar
  145. 145.
    Lin CH, Hsu CW, Chiang YJ, Ng KF, Chiu CT. Esophageal and gastric kaposi’s sarcomas presenting as upper gastrointestinal bleeding. Chang Gung Med J. 2002;25:329–333.PubMedGoogle Scholar
  146. 146.
    Danzig JB, Brandt LJ, Reinus JF, Klein RS. Gastrointestinal malignancy in patients with aids. Am J Gastroenterol. 1991;86:715–718.PubMedGoogle Scholar
  147. 147.
    Friedman SL, Wright TL, Altman DF. Gastrointestinal kaposi’s sarcoma in patients with acquired immunodeficiency syndrome. Endoscopic and autopsy findings. Gastroenterology. 1985;89:102–108.PubMedGoogle Scholar
  148. 148.
    Ioachim HL, Adsay V, Giancotti FR, Dorsett B, Melamed J. Kaposi’s sarcoma of internal organs. A multiparameter study of 86 cases. Cancer. 1995;75:1376–1385. doi :10.1002/1097-0142(19950315)75:6<1376::AID-CNCR2820750621>3.0.CO;2-Y.PubMedCrossRefGoogle Scholar
  149. 149.
    Frances C. Kaposi’s sarcoma after renal transplantation. Nephrol Dial Transplant. 1998;13:2768–2773. doi: 10.1093/ndt/13.11.2768.PubMedCrossRefGoogle Scholar
  150. 150.
    Dezube BJ. Management of aids-related kaposi’s sarcoma: advances in target discovery and treatment. Expert Rev Anticancer Ther. 2002;2:193–200. doi: 10.1586/14737140.2.2.193.PubMedCrossRefGoogle Scholar
  151. 151.
    Lee FC, Mitsuyasu RT. Chemotherapy of aids––related kaposi’s sarcoma. Hematol Oncol Clin North Am. 1996;10:1051–1068. doi: 10.1016/S0889-8588(05)70384-1.PubMedCrossRefGoogle Scholar
  152. 152.
    Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M. Malignancy in renal transplantation. J Am Soc Nephrol. 2004;15:1582–1588. doi: 10.1097/01.ASN.0000126194.77004.9B.PubMedCrossRefGoogle Scholar
  153. 153.
    Kanj SS, Sharara AI, Clavien PA, Hamilton JD. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis. 1996;22:537–549.PubMedGoogle Scholar
  154. 154.
    Wong NA, Bathgate AJ, Bellamy CO. Colorectal disease in liver allograft recipients––a clinicopathological study with follow-up. Eur J Gastroenterol Hepatol. 2002;14:231–236. doi: 10.1097/00042737-200203000-00005.PubMedCrossRefGoogle Scholar
  155. 155.
    Singh N, Wannstedt C, Keyes L, et al. Impact of evolving trends in recipient and donor characteristics on cytomegalovirus infection in liver transplant recipients. Transplantation. 2004;77:106–110. doi: 10.1097/01.TP.0000101289.80832.37.PubMedCrossRefGoogle Scholar
  156. 156.
    van de Vrie W, de Man RA, van Buuren HR, Schouten WR, Tilanus HW, Metselaar HJ. Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis. Eur J Gastroenterol Hepatol. 2003;15:657–663. doi: 10.1097/00042737-200306000-00013.PubMedCrossRefGoogle Scholar
  157. 157.
    Ardizzone S, Bianchi Porro G. Inflammatory bowel disease: new insights into pathogenesis and treatment. J Intern Med. 2002;252:475–496. doi: 10.1046/j.1365-2796.2002.01067.x.PubMedCrossRefGoogle Scholar
  158. 158.
    Riley TR, Schoen RE, Lee RG, Rakela J. A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol. 1997;92:279–282.PubMedGoogle Scholar
  159. 159.
    Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology. 1983;85:713–717.PubMedGoogle Scholar
  160. 160.
    Dvorchik I, Subotin M, Demetris AJ, et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology. 2002;35:380–384. doi: 10.1053/jhep.2002.30695.PubMedCrossRefGoogle Scholar
  161. 161.
    Papatheodoridis GV, Hamilton M, Mistry PK, Davidson B, Rolles K, Burroughs AK. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut. 1998;43:639–644.PubMedCrossRefGoogle Scholar
  162. 162.
    Worns MA, Lohse AW, Neurath MF, et al. Five cases of de novo inflammatory bowel disease after orthotopic liver transplantation. Am J Gastroenterol. 2006;101:1931–1937. doi: 10.1111/j.1572-0241.2006.00624.x.PubMedCrossRefGoogle Scholar
  163. 163.
    Wahbeh G, Hupertz V, Hallowell S, Patel R, Chrisant MR. Idiopathic colitis following cardiac transplantation: three pediatric cases. Pediatr Transplant. 2003;7:464–468. doi: 10.1046/j.1399-3046.2003.00098.x.PubMedCrossRefGoogle Scholar
  164. 164.
    Ramji A, Owen DA, Erb SR, Scudamore CH, Yoshida EM. Post-liver transplant crohn’s disease: graft tolerance but not self-tolerance? Dig Dis Sci. 2002;47:522–527. doi: 10.1023/A:1017951632444.PubMedCrossRefGoogle Scholar
  165. 165.
    Holtmann MH, Neurath MF. Transplanting the genetic susceptibility to crohn’s disease. Gut. 2003;52:1394–1396. doi: 10.1136/gut.52.10.1394.PubMedCrossRefGoogle Scholar
  166. 166.
    Niessner M, Volk BA. Phenotypic and immunoregulatory analysis of intestinal t-cells in patients with inflammatory bowel disease: evaluation of an in vitro model. Eur J Clin Invest. 1995;25:155–164. doi: 10.1111/j.1365-2362.1995.tb01542.x.PubMedCrossRefGoogle Scholar
  167. 167.
    Senju M, Hulstaert F, Lowder J, Jewell DP. Flow cytometric analysis of peripheral blood lymphocytes in ulcerative colitis and crohn’s disease. Gut. 1991;32:779–783. doi: 10.1136/gut.32.7.779.PubMedCrossRefGoogle Scholar
  168. 168.
    Haagsma EB, Van Den Berg AP, Kleibeuker JH, Slooff MJ, Dijkstra G. Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment Pharmacol Ther. 2003;18:33–44. doi: 10.1046/j.1365-2036.2003.01613.x.PubMedCrossRefGoogle Scholar
  169. 169.
    Lundqvist K, Broome U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum. 1997;40:451–456. doi: 10.1007/BF02258391.PubMedCrossRefGoogle Scholar
  170. 170.
    Verdonk RC, Dijkstra G, Haagsma EB, et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant. 2006;6:1422–1429. doi: 10.1111/j.1600-6143.2006.01333.x.PubMedCrossRefGoogle Scholar
  171. 171.
    Moayyeri A, Daryani NE, Bahrami H, Haghpanah B, Nayyer-Habibi A, Sadatsafavi M. Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis. J Gastroenterol Hepatol. 2005;20:366–370. doi: 10.1111/j.1440-1746.2005.03727.x.PubMedCrossRefGoogle Scholar
  172. 172.
    Befeler AS, Lissoos TW, Schiano TD, et al. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation. 1998;65:393–396. doi: 10.1097/00007890-199802150-00017.PubMedCrossRefGoogle Scholar
  173. 173.
    Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338:1741–1751. doi: 10.1056/NEJM199806113382407.PubMedCrossRefGoogle Scholar
  174. 174.
    Fujinami RS, Nelson JA, Walker L, Oldstone MB. Sequence homology and immunologic cross-reactivity of human cytomegalovirus with hla-dr beta chain: a means for graft rejection and immunosuppression. J Virol. 1988;62:100–105.PubMedGoogle Scholar
  175. 175.
    Vega R, Bertran X, Menacho M, et al. Cytomegalovirus infection in patients with inflammatory bowel disease. Am J Gastroenterol. 1999;94:1053–1056. doi: 10.1111/j.1572-0241.1999.01013.x.PubMedCrossRefGoogle Scholar
  176. 176.
    Wada Y, Matsui T, Matake H, et al. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum. 2003;46:S59–S65. doi: 10.1007/s10350-004-6497-1.PubMedCrossRefGoogle Scholar
  177. 177.
    Crowley B, Dempsey J, Olujohungbe A, Khan A, Mutton K, Hart CA. Unusual manifestations of primary cytomegalovirus infection in patients without hiv infection and without organ transplants. J Med Virol. 2002;68:237–240. doi: 10.1002/jmv.10200.PubMedCrossRefGoogle Scholar
  178. 178.
    Kishore J, Ghoshal U, Ghoshal UC, et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol. 2004;53:1155–1160. doi: 10.1099/jmm.0.45629-0.PubMedCrossRefGoogle Scholar
  179. 179.
    Lennard-Jones JE, Melville DM, Morson BC, Ritchie JK, Williams CB. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. Gut. 1990;31:800–806. doi: 10.1136/gut.31.7.800.PubMedCrossRefGoogle Scholar
  180. 180.
    Loftus EVJ, Aguilar HI, Sandborn WJ, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology. 1998;27:685–690. doi: 10.1002/hep.510270308.PubMedCrossRefGoogle Scholar
  181. 181.
    Fabia R, Levy MF, Testa G, et al. Colon carcinoma in patients undergoing liver transplantation. Am J Surg. 1998;176:265–269. doi: 10.1016/S0002-9610(98)00141-X.PubMedCrossRefGoogle Scholar
  182. 182.
    Vera A, Gunson BK, Ussatoff V, et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation. 2003;75:1983–1988. doi: 10.1097/01.TP.0000058744.34965.38.PubMedCrossRefGoogle Scholar
  183. 183.
    Itzkowitz SH, Present DH. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314–321. doi: 10.1097/01.MIB.0000160811.76729.d5.PubMedCrossRefGoogle Scholar
  184. 184.
    Bartlett JG. Clostridium difficile: clinical considerations. Rev Infect Dis. 1990;12(Suppl 2):S243–S251.PubMedGoogle Scholar
  185. 185.
    Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330:257–262. doi: 10.1056/NEJM199401273300406.PubMedCrossRefGoogle Scholar
  186. 186.
    Willingham FF, Ticona Chavez E, Taylor DN, et al. Diarrhea andClostridium difficile infection in latin American patients with aids. Working group on aids in Peru. Clin Infect Dis. 1998;27:487–493. doi: 10.1086/514688.PubMedCrossRefGoogle Scholar
  187. 187.
    Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26:273–280. doi: 10.1086/502539.PubMedCrossRefGoogle Scholar
  188. 188.
    Hashimoto M, Sugawara Y, Tamura S, et al. Clostridium difficile-associated diarrhea after living donor liver transplantation. World J Gastroenterol. 2007;13:2072–2076.PubMedGoogle Scholar
  189. 189.
    Kyne L, Sougioultzis S, McFarland LV, Kelly CP. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol. 2002;23:653–659. doi: 10.1086/501989.PubMedCrossRefGoogle Scholar
  190. 190.
    Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235:363–372. doi: 10.1097/00000658-200203000-00008.PubMedCrossRefGoogle Scholar
  191. 191.
    Wanahita A, Goldsmith EA, Musher DM. Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by Clostridium difficile. Clin Infect Dis. 2002;34:1585–1592. doi: 10.1086/340536.PubMedCrossRefGoogle Scholar
  192. 192.
    Seppala K, Hjelt L, Sipponen P. Colonoscopy in the diagnosis of antibiotic-associated colitis. A prospective study. Scand J Gastroenterol. 1981;16:465–468.PubMedCrossRefGoogle Scholar
  193. 193.
    Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum. 1995;38:350–354. doi: 10.1007/BF02054220.PubMedCrossRefGoogle Scholar
  194. 194.
    Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva JJ. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995;16:459–477.PubMedCrossRefGoogle Scholar
  195. 195.
    George WL, Rolfe RD, Finegold SM. Clostridium difficile and its cytotoxin in feces of patients with antimicrobial agent-associated diarrhea and miscellaneous conditions. J Clin Microbiol. 1982;15:1049–1053.PubMedGoogle Scholar
  196. 196.
    Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346:334–339. doi: 10.1056/NEJMcp011603.PubMedCrossRefGoogle Scholar
  197. 197.
    Tedesco FJ. Antibiotic associated pseudomembranous colitis with negative proctosigmoidoscopy examination. Gastroenterology. 1979;77:295–297.PubMedGoogle Scholar
  198. 198.
    Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut. 1986;27:1169–1172. doi: 10.1136/gut.27.10.1169.PubMedCrossRefGoogle Scholar
  199. 199.
    Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet. 1983;2:1043–1046. doi: 10.1016/S0140-6736(83)91036-X.PubMedCrossRefGoogle Scholar
  200. 200.
    Fekety R, Silva J, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med. 1989;86:15–19. doi: 10.1016/0002-9343(89)90223-4.PubMedCrossRefGoogle Scholar
  201. 201.
    Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis. 2005;5:549–557. doi: 10.1016/S1473-3099(05)70215-2.PubMedCrossRefGoogle Scholar
  202. 202.
    Johnson S, Gerding DN, Olson MM, et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med. 1990;88:137–140. doi: 10.1016/0002-9343(90)90462-M.PubMedCrossRefGoogle Scholar
  203. 203.
    Orlando G, Ferrant A, Schots R, et al. Liver transplantation for chronic graft-versus-host disease: case report with 10-year follow-up. Transpl Int. 2005;18:125–129. doi: 10.1111/j.1432-2277.2004.00008.x.PubMedCrossRefGoogle Scholar
  204. 204.
    Ginsburg PM, Thuluvath PJ. Diarrhea in liver transplant recipients: etiology and management. Liver Transpl. 2005;11:881–890. doi: 10.1002/lt.20500.PubMedCrossRefGoogle Scholar
  205. 205.
    Kamei H, Oike F, Fujimoto Y, Yamamoto H, Tanaka K, Kiuchi T. Fatal graft-versus-host disease after living donor liver transplantation: differential impact of donor-dominant one-way hla matching. Liver Transpl. 2006;12:140–145. doi: 10.1002/lt.20573.PubMedCrossRefGoogle Scholar
  206. 206.
    Matthes-Martin S, Aberle SW, Peters C, et al. Cmv-viraemia during allogenic bone marrow transplantation in paediatric patients: association with survival and graft-versus-host disease. Bone Marrow Transplant. 1998;21(Suppl 2):S53–S56.PubMedGoogle Scholar
  207. 207.
    Perri R, Assi M, Talwalkar J, et al. Graft vs. Host disease after liver transplantation: a new approach is needed. Liver Transpl. 2007;13:1092–1099. doi: 10.1002/lt.21203.PubMedCrossRefGoogle Scholar
  208. 208.
    Taylor AL, Gibbs P, Bradley JA. Acute graft versus host disease following liver transplantation: the enemy within. Am J Transplant. 2004;4:466–474. doi: 10.1111/j.1600-6143.2004.00406.x.PubMedCrossRefGoogle Scholar
  209. 209.
    Smith DM, Agura E, Netto G, et al. Liver transplant-associated graft-versus-host disease. Transplantation. 2003;75:118–126. doi: 10.1097/00007890-200301150-00022.PubMedCrossRefGoogle Scholar
  210. 210.
    Whalen JG, Jukic DM. English JCr: rash and pancytopenia as initial manifestations of acute graft-versus-host disease after liver transplantation. J Am Acad Dermatol. 2005;52:908–912. doi: 10.1016/j.jaad.2005.01.126.PubMedCrossRefGoogle Scholar
  211. 211.
    Whitington PF, Rubin CM, Alonso EM, et al. Complete lymphoid chimerism and chronic graft-versus-host disease in an infant recipient of a hepatic allograft from an HLA-homozygous parental living donor. Transplantation. 1996;62:1516–1519. doi: 10.1097/00007890-199611270-00025.PubMedCrossRefGoogle Scholar
  212. 212.
    Domiati-Saad R, Klintmalm GB, Netto G, Agura ED, Chinnakotla S, Smith DM. Acute graft versus host disease after liver transplantation: patterns of lymphocyte chimerism. Am J Transplant. 2005;5:2968–2973. doi: 10.1111/j.1600-6143.2005.01110.x.PubMedCrossRefGoogle Scholar
  213. 213.
    Schrager JJ, Vnencak-Jones CL, Graber SE, et al. Use of short tandem repeats for DNA fingerprinting to rapidly diagnose graft-versus-host disease in solid organ transplant patients. Transplantation. 2006;81:21–25. doi: 10.1097/01.tp.0000190431.94252.3f.PubMedCrossRefGoogle Scholar
  214. 214.
    Bombi JA, Nadal A, Carreras E, et al. Assessment of histopathologic changes in the colonic biopsy in acute graft-versus-host disease. Am J Clin Pathol. 1995;103:690–695.PubMedGoogle Scholar
  215. 215.
    Walling HW, Voigt MD, Stone MS. Lichenoid graft vs. host disease following liver transplantation. J Cutan Pathol. 2004;31:179–184. doi: 10.1111/j.0303-6987.2004.00146.x.PubMedCrossRefGoogle Scholar
  216. 216.
    Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81:1390–1397. doi: 10.1097/01.tp.0000214462.63943.14.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Sharad Sharma
    • 1
    Email author
  • Ahmet Gurakar
    • 1
  • Cemalettin Camci
    • 1
  • Nicolas Jabbour
    • 1
  1. 1.Nazih Zuhdi Transplant InstituteOklahoma CityUSA

Personalised recommendations